Jaguar Health, Inc. has announced initial proof-of-concept results from an ongoing investigator-initiated trial (IIT) demonstrating that their novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) in pediatric patients with intestinal failure due to the orphan diseases, short bowel syndrome (SBS-IF) and microvillus inclusion disease (MVID). These results, which indicate a reduction in TPN requirements by up to 27% in MVID patients and up to 12.5% in SBS-IF patients, have been submitted for consideration for presentation at a major international pediatric gastroenterological conference. The company is pursuing business development partnerships to support the development and commercialization of its intestinal failure products, seeking non-dilutive funding. Additionally, a Phase 2 study of crofelemer in pediatric MVID patients is underway, with completion expected in mid-2026.